P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS

• Allison Rosenthal,
• Monika Jun,
• Javier Munoz,
• Tongsheng Wang,
• Alex Mutebi,
• Anthony Wang,
• Shibing Yang,
• Kojo Osei-Bonsu,
• Brian Elliott,
• Anupama Kalsekar,
• Fernando Rivas Navarro,
• Andrew Ip

Affiliations

Allison Rosenthal

1 Mayo Clinic, Phoenix, United States

Monika Jun

2 Genmab US, Inc., Princeton, United States

Javier Munoz

1 Mayo Clinic, Phoenix, United States

Tongsheng Wang

2 Genmab US, Inc., Princeton, United States

Alex Mutebi

2 Genmab US, Inc., Princeton, United States

Anthony Wang

3 AbbVie, Inc, North Chicago, United States

Shibing Yang

2 Genmab US, Inc., Princeton, United States

Kojo Osei-Bonsu

3 AbbVie, Inc, North Chicago, United States

Brian Elliott

2 Genmab US, Inc., Princeton, United States

Anupama Kalsekar

2 Genmab US, Inc., Princeton, United States

Fernando Rivas Navarro

4 Genmab A/S, Copenhagen, Denmark

Andrew Ip

5 Hackensack University Medical Center, Hackensack, United States